Medimmune Limited

Gianluca Carlesso

Changshou Gao

Scott A Hammond

Claire Louise Dobson

Ronald Herbst

Darren Schofield

Godfrey Rainey

Stacey Drabic

Michelle Morrow

Srinath Kasturirangan

Yariv Mazor

Brian Lobo

Michael Oberst

Prakash Manikwar

Jonathan Seaman

Simon Dovedi

Kristen Pollizzi

Anthony Coyle

Michael A Bowen

Ambarish Shah

Yihong Yao

Hasige Sathish

Bahija Jallal

Tracy Delaney

Michael Bowen

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Growing community of inventors

Gaithersburg, MD, United States of America

Gianluca Carlesso